| QUESTIONS AND ANSWERS | | | |||||
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 5 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 8 | | | |
| | | | | 9 | | | |
| | | | | 10 | | | |
| | | | | 11 | | | |
| | | | | 11 | | | |
| | | | | 11 | | | |
| | | | | 11 | | | |
| | | | | 11 | | | |
| | | | | 11 | | | |
| | | | | 13 | | | |
| | | | | 14 | | | |
| | | |
|
| | ||
| | | | | 15 | | | |
|
Summary Compensation Table
|
| | | | 15 | | |
| | | | | 16 | | | |
| | | | | 18 | | | |
| | | | | 18 | | | |
| | | | | 20 | | | |
| | | | | 20 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 25 | | | |
| | | | | 26 | | | |
| | | | | 27 | | | |
| | | | | 28 | | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | A-1 | | |
Name
|
| |
Age
|
| |
Position
|
| |
Director
Since |
|
Lindsay A. Rosenwald, M.D.
|
| |
62
|
| | Chairman of the Board of Directors | | |
2015
|
|
Lucy Lu, M.D. | | |
43
|
| | President, Chief Executive Officer, and Director | | |
2015
|
|
Neil Herskowitz | | |
61
|
| | Director | | |
2015
|
|
Jay Kranzler, M.D., PhD | | |
60
|
| | Director | | |
2017
|
|
Jeffrey Paley, M.D. | | |
50
|
| | Director | | |
2015
|
|
Akhtar Samad, M.D., PhD | | |
58
|
| | Director | | |
2015
|
|
Michael S. Weiss | | |
52
|
| | Director | | |
2015
|
|
Name
|
| |
Age
|
| |
Position
|
|
Lindsay A. Rosenwald, M.D. | | |
62
|
| | Executive Chairman | |
Lucy Lu, M.D. | | |
43
|
| | President, Chief Executive Officer and Director | |
Joseph Vazzano | | |
34
|
| | Vice President, Finance and Accounting and Principal Financial Officer | |
Scott A. Reines, M.D., PhD | | |
71
|
| | Interim Chief Medical Officer | |
Name and Principal Position
|
| |
Year
|
| |
Salary ($)
|
| |
Bonus ($)
|
| |
Stock
Awards ($)(1) |
| |
Total ($)
|
| |||||||||||||||
Lucy Lu(2)
Chief Executive Officer |
| | | | 2017 | | | | | | 294,940(2) | | | | | | 282,625(5) | | | | | | 1,455,550 | | | | | | 2,033,115 | | |
| | | 2016 | | | | | | 181,132(2) | | | | | | 135,800(6) | | | | | | 27,875 | | | | | | 344,807 | | | ||
Joseph Vazzano
Vice President of Finance and Corporate Controller |
| | | | 2017 | | | | | | 74,756(3) | | | | | | 48,630 | | | | | | 203,100 | | | | | | 326,486 | | |
Scott A. Reines
Interim Chief Medical Officer |
| | | | 2017 | | | | | | 38,100(4) | | | | | | — | | | | | | 126,700 | | | | | | 164,800 | | |
| | | 2016 | | | | | | 43,175(4) | | | | | | — | | | | | | — | | | | | | 43,175 | | |
Name
|
| |
Grant Date
|
| |
Number of
Shares or Units of Stock that Have Not Vested |
| |
Market Value
of Shares or Units of Stock that Have Not Vested ($)(1) |
| |
Equity Incentive
Plan Awards: Number of Unearned Shares, Units or Other Rights that Hare Not Vested |
| |
Equity Incentive
Plan Awards: Market Value or Payout Value of Unearned Shares, Units or Other Rights that Have Not Vested ($)(1) |
| |||||||||||||||
Lucy Lu
|
| | | | 6/10/2015 | | | | | | 83,332(2) | | | | | | 301,662 | | | | | | 116,667(2) | | | | | | 422,335 | | |
Lucy Lu
|
| | | | 8/8/2017 | | | | | | 215,000(3) | | | | | | 778,300 | | | | | | — | | | | | | — | | |
Joseph Vazzano
|
| | | | 8/8/2017 | | | | | | 30,000(3) | | | | | | 108,600 | | | | | | — | | | | | | — | | |
Scott Reines
|
| | | | 8/8/2017 | | | | | | 35,000(3) | | | | | | 126,700 | | | | | | — | | | | | | — | | |
Name
|
| |
Fees Earned
or Paid in Cash(1) |
| |
Stock Awards
($)(2) |
| |
Total ($)
|
| |||||||||
Lindsay A. Rosenwald
|
| | | | 30,000 | | | | | | 67,700 | | | | | | 97,700 | | |
Michael S. Weiss
|
| | | | 25,000 | | | | | | 67,700 | | | | | | 92,700 | | |
Neil Herskowitz
|
| | | | 30,000 | | | | | | 338,500 | | | | | | 368,500 | | |
Jeffrey Paley
|
| | | | 25,000 | | | | | | 338,500 | | | | | | 363,500 | | |
Akhtar Samad
|
| | | | 25,000 | | | | | | 338,500 | | | | | | 363,500 | | |
Jay Kranzler
|
| | | | 25,000 | | | | | | 338,500 | | | | | | 363,500 | | |
| | | | | | | | |
Percentage of Shares
Benefically Owned |
| ||||||
Name of Beneficial Owner
|
| |
Number of Shares
Benefically Owned |
| |
Before
Offering |
| |
After
Offering |
| ||||||
Lucy Lu
|
| | | | 337,333 | | | | | | 3% | | | | ||
Joseph Vazzano
|
| | | | — | | | | | | * | | | | ||
Scott A. Reines
|
| | | | — | | | | | | * | | | | ||
Lindsay A. Rosenwald
|
| | | | 186,667(1) | | | | | | 2% | | | | ||
Michael S. Weiss
|
| | | | 176,667(1) | | | | | | 2% | | | | ||
Neil Herskowitz
|
| | | | 51,500 | | | | | | * | | | | ||
Jeffrey Paley
|
| | | | 50,000 | | | | | | * | | | | ||
Akhtar Samad
|
| | | | 50,000 | | | | | | * | | | | ||
Jay Kranzler
|
| | | | 50,000 | | | | | | * | | | | ||
All Executive officers and directors as a group (9 persons)
|
| | | | 568,833(2) | | | | | | 5% | | | | ||
5% or Greater Stockholders: | | | | | ||||||||||||
Fortress Biotech, Inc.
|
| | | | 3,590,096(3) | | | | | | 34% | | | |
| AVENUE THERAPEUTICS, INC. | | |||
| By: | | | | |
| | | | Lucy Lu, M.D. President, Chief Executive Officer and Director |
|